Session Information
-
WCLC 2022
2022 World Conference on Lung Cancer
Conference Program for 2022 the World Conference on Lung Cancer
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2137
All times listed are in Vienna, Austria Time, CEST (UTC+2:00)
PL - Plenary
IBS - Interactive Breakfast Session (in-person attendees only)
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
P - Posters
EP - ePosters
WS - Workshops
LA – Lectureship Awards
IS - Industry Symposium
August 5 Fri
Aug 5 Saturday
August 6 Sat
Aug 6 Sunday
August 7 Sun
Aug 7 Monday
August 8 Mon
Aug 8 Tuesday
August 9 Tue
Aug 9
-
+
OA03 - Molecular Targeted Treatments
- 14:30 - 15:40
- 8/07/2022
- Location: Hall C7
- Not for CME Credit
- Type: Oral
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Moderators:Andrew Ciupek, David R. Gandara
-
+
OA03.06 - CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC
15:02 - 15:12 | Presenter: Bob T. Li
- Abstract
Loading...
-
+
EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
-
+
EP08.02-019 - Phase 1/2 Study of BLU-701, a Highly Selective EGFR Inhibitor, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Presenter: Alexander Spira- Abstract
Loading... -
+
EP08.02-125 - Tumor Suppressor Gene Alterations Identified at Disease Progression Impact Outcomes in Patients with EGFR-mutant Lung Cancer
Presenter: Paul Stockhammer- Abstract
Loading...
-
+
P1.10 - Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy
- 17:00 - 19:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: Regular Poster
- Track: Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy
-
+
P1.10-01 - Phase 3 Study of Durvalumab Combined with Oleclumab or Monalizumab in Patients with Unresectable Stage III NSCLC (PACIFIC-9)
Presenter: Aarthi Gopinathan- Abstract
Loading...